Targeted agents for second-line treatment of advanced hepatocellular carcinoma

doi:10.4251/wjgo.v11.i10.788

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7479)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-6) series.

Item

Count

PDF

434

WORD

269

HTML

3687

Tables (1-6)

227

Sum=4617

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

504

Download

792

Sum=1296

Publishing Process of This Article

Item

Count

Browse

714

Download

852

Sum=1566

Oct 15, 2019 (publication date) through Nov 20, 2024

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Oncol. Oct 15, 2019; 11(10): 788-803
Published online Oct 15, 2019. doi: 10.4251/wjgo.v11.i10.788

Table 1 Efficacy results of the RESORCE phase III trial

Outcome based on assessment per mRECIST	Regorafenib n = 379 (%)	Placebo n = 194 (%)	HR (95%CI)	P value
Response
Complete	2 (1)	0	-	NR
Partial	38 (10)	8 (4)	-	NR
Overall response rate	40 (11)	8 (4)	-	0.0047
Stable disease	206 (54)	62 (32)	-	NR
Disease control rate	247 (65)	70 (36)	-	< 0.0001
Overall survival in mo
Median	10.6	7.8	0.63	< 0.0001
95%CI	9.1-12.1	6.3-8.8	(0.50-0.79)
Progression-free survival in mo
Median	3.1	1.5	0.46	< 0.0001
95%CI	2.8-4.2	1.4-1.6	(0.37-0.56)
Time to progression in mo
Median	3.2	1.5	0.44	< 0.0001
95%CI	(2.9-4.2)	(1.4-1.6)	(0.36-0.55)
Outcome based on assessment per RECIST 1.1
Response
Complete	0	0	-	NR
Partial	25 (7)	5 (3)	-	NR
Overall response rate	25 (7)	5 (3)	-	0.02
Stable disease	223 (59)	62 (32)	-	NR
Disease control rate	249 (66)	67 (35)	-	< 0.0001
Progression-free survival in mo
Median	3.4	1.5	0.43	< 0.0001
95%CI	2.9-4.2	1.4-1.5	(0.35-0.52)
Time to progression in mo
Median	3.9	1.5	0.41	< 0.0001
95%CI	(2.9-4.2)	(1.4-1.6)	(0.34-0.51)

Adapted from: Bruix et al[14]; Bruix et al[18]. CI: Confidence interval; NR: Not reported; HR: Hazard ratio.

Table 2 Adverse events in the RESORCE phase III trial occurring in ≥ 10% of patients–Safety population

	Adverse events, n (%)						Treatment-related adverse events, n (%)
	Regorafenib			Placebo			Regorafenib			Placebo
	n = 374			n = 193			n = 374			n = 193
	Any G	G 3	G 4	Any G	G 3	G 4	Any G	G 3	G 4	Any G	G 3	G 4
Any AE	374 (100)	208 (56)	40 (11)	179 (93)	61 (32)	14 (7)	346 (93)	173 (46)	14 (4)	100 (52)	31 (16)	1 (1)
HFSR	198 (53)	47 (13)	NA	15 (8)	1 (1)	NA	196 (52)	47 (13)	NA	13 (7)	1 (1)	NA
Diarrhea	155 (41)	12 (3)	0	29 (15)	0	NA	125 (33)	9 (2)	0	18 (9)	0	0
Fatigue	151 (40)	34 (9)	NA	61 (32)	9 (5)	NA	110 (29)	24 (6)	NA	37 (19)	3 (2)	NA
Hypertension	116 (31)	56 (15)	1 (< 1)	12 (6)	9 (5)	0	87 (23)	48 (13)	1 (< 1)	9 (5)	6 (3)	0
Anorexia	116 (31)	10 (3)	0	28 (15)	4 (2)	0	88 (24)	10 (3)	0	12 (6)	0	0
Increased bilirubin	108 (29)	37 (10)	2 (1)	34 (18)	15 (8)	6 (3)	70 (19)	24 (6)	1 (< 1)	7 (4)	4 (2)	0
Increased AST	92 (25)	37 (10)	4 (1)	38 (20)	19 (10)	3 (2)	48 (13)	16 (4)	3 (1)	15 (8)	9 (5)	1 (1)
Fever	72 (19)	0	0	14 (7)	0	0	14 (4)	0	0	4 (2)	0	0
Nausea	64 (17)	2 (1)	NA	26 (13)	0	NA	40 (11)	1 (< 1)	NA	13 (7)	0	NA
Increased ALT	55 (15)	10 (3)	2 (1)	22 (11)	5 (3)	0	29 (8)	6 (2)	2 (1)	8 (4)	2 (1)	0
Weight loss	51 (14)	7 (2)	NA	9 (5)	0	NA	27 (7)	4 (1)	NA	3 (2)	0	NA
Oral mucositis	47 (13)	4 (1)	0	6 (3)	1 (1)	0	42 (11)	4 (1)	0	5 (3)	1 (1)	0
Vomiting	47 (13)	3 (1)	0	13 (7)	1 (1)	0	27 (7)	1 (< 1)	0	5 (3)	0	0
Cough	40 (11)	1 (< 1)	NA	14 (7)	0	NA	4 (1)	0	NA	2 (1)	0	NA
Hypophosphatemia	37 (10)	30 (8)	2 (1)	4 (2)	3 (2)	0	22 (6)	16 (4)	2 (1)	2 (1)	1(1)	0
Hoarseness	39 (10)	0	NA	1 (1)	0	NA	34 (9)	0	NA	0	0	NA

Adapted from: Bruix et al[14]. G: Grade; AE: Adverse event; HFSR: Hand-foot skin reaction; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; NA: Not applicable.

Table 3 Efficacy results of the CELESTIAL phase III trial

Outcome	Cabozantinib	Placebo	HR	P value
Intent to treat population	n = 470 (%)	n = 237 (%)	(95%CI)
Overall response rate				0.009
Partial response	18 (4)	1 (< 1)	-
95%CI	(2.3-6.0)	(0.0-2.3)
Stable disease	282 (60)	78 (33)	-	NR
Disease control rate	300 (64)	79 (33)	-	NR
Overall survival in mo
Median	10.2	8.0	0.76	0.005
95%CI	9.1-12.0	6.8-9.4	(0.63-0.92)
Progression-free survival in mo
Median	5.2	1.9	0.44	< 0.001
95%CI	4.0-5.5	1.9-1.9	(0.36-0.52)
Time to progression in mo				NR
Median	5.4	1.9	0.41
95%CI	(4.0-5.6)	(1.9-1.9)	(0.34-0.49)
Patients who have only received sorafenib as prior therapy	n = 335 (%)	n = 174 (%)	HR (95%CI)	P value
Overall survival in mo
Median	11.3	7.2	0.70	NR
95%CI	9.5-13.9	5.8-9.3	(0.55-0.88)
Progression-free survival in mo
Median	5.5	1.9	0.40	NR
95%CI	4.6-5.7	1.9-1.9	(0.32-0.50)

Adapted from: Abou-Alfa et al[34]; Merle et al[35]; Kelley et al[36]. CI: Confidence interval; NR: Not reported; HR: Hazard ratio.

Table 4 Adverse events in the CELESTIAL phase III trial occurring in ≥ 10% of patients regardless of causality–Safety population

	Adverse events, n (%)
	Cabozantinib		Placebo
	n = 467		n = 237
	Any G	G 3-4¹	Any G	G 3-4¹
Any AE	460 (99)	316 (68)	219 (92)	86 (37)
Diarrhea	251 (54)	46 (10)	44 (19)	4 (2)
Decreased appetite	225 (48)	27 (6)	43 (18)	1 (< 1)
PPE	217 (46)	79 (17)	12 (5)	0
Fatigue	212 (45)	49 (10)	70 (30)	10 (4)
Nausea	147 (31)	10 (2)	42 (18)	4 (2)
Hypertension	137 (29)	74 (16)	14 (6)	4 (2)
Vomiting	121 (26)	2 (< 1)	28 (12)	6 (3)
Increased AST	105 (22)	55 (12)	27 (11)	16 (6)
Asthenia	102 (22)	32 (7)	18 (8)	4 (2)
Dysphonia	90 (19)	3 (1)	5 (2)	0
Constipation	87 (19)	2 (< 1)	45 (19)	0
Abdominal pain	83 (18)	8 (1)	60 (25)	10 (4)
Weight loss	81 (17)	5 (1)	14 (6)	0
Increased ALT	80 (17)	23 (5)	13 (5)	5 (2)
Mucosal inflammation	65 (14)	8 (2)	5 (2)	1 (< 1)
Fever	64 (14)	0	24 (10)	1 (< 1)
Upper abdominal pain	63 (13)	3 (1)	31 (13)	0
Cough	63 (13)	1 (< 1)	26 (11)	0
Peripheral edema	63 (13)	4 (1)	32 (14)	2 (1)
Stomatitis	63 (13)	8 (2)	5 (2)	0
Dyspnea	58 (12)	15 (3)	24 (10)	1 (< 1)
Rash	58 (12)	2 (< 1)	146 (6)	1 (< 1)
Ascites	57 (12)	18 (4)	30 (13)	11 (5)
Dysgeusia	56 (12)	0	5 (2)	0
Hypoalbuminemia	55 (12)	2 (< 1)	12 (5)	0
Headache	52 (11)	1 (< 1)	16 (7)	1 (< 1)
Thrombocytopenia	52 (11)	16 (3)	1 (< 1)	0

¹Mostly grade 3; Adapted from: Abou-Alfa et al[34]. G: Grade; AE: Adverse event; PPE: Palmar-plantar erythrodysesthesia; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase.

Table 5 Efficacy results of the REACH-2 phase III trial

Outcome	Ramucirumab n = 197 (%)	Placebo n = 95 (%)	HR (95%CI)	P value
Response
Complete	0	0	-	NR
Partial	9 (4.6)	1 (1.1)	-	NR
Overall response rate	9 (4.6)	1 (1.1)	-	0.1697
Stable disease	109 (55.3)	36 (37.9)	-	NR
Disease control rate	118 (59.9)	37 (38.9)	-	0.0006
Overall survival in mo			0.71 (0.53–0.94)	0.0199
Median	8.5	7.3
95%CI	7.0-10.6	5.4-9.1
Progression-free survival in mo			0.45 (0.33–0.60)	< 0.0001
Median	2.8	1.6
95%CI	2.8–4.1	1.5–2.7
Time to progression in mo			0.42 (0.31–0.58)	< 0.0001
Median	3.0	1.6
95%CI	(2.8–4.2)	(1.5–2.7)

Adapted from: Zhu et al[57]. CI: Confidence interval; NR: Not reported; HR: Hazard ratio.

Table 6 Adverse events in the REACH-2 phase III trial occurring in ≥ 10% of patients–Safety population

	Adverse events, n (%)						Treatment-related adverse events, n (%)
	Ramucirumab			Placebo			Ramucirumab			Placebo
	n = 197			n = 95			n = 197			n = 95
	Any G	G 3	G 4	Any G	G 3	G 4	Any G	G 3	G 4	Any G	G3	G 4
Fatigue	54 (27)	7 (4)	NA	16 (17)	3 (3)	NA	28 (14)	2 (1)	NA	5 (5)	0	NA
Peripheral edema	50 (25)	3 (2)	0	13 (14)	0	0	15 (8)	2 (1)	0	5 (5)	0	0
Decreased appetite	46 (23)	3 (2)	0	19 (20)	1 (1)	0	21 (11)	0	NA	4 (4)	0	0
Abdominal pain	39 (20)	3 (2)	NA	12 (13)	2 (2)	NA	8 (4)	1 (1)	1 (< 1)	3 (3)	0	NA
Nausea	37 (19)	0	NA	11 (12)	0	NA	23 (12)	0	0	2 (2)	0	NA
Diarrhea	32 (16)	0	0	13 (14)	1 (1)	0	14 (7)	0	1 (< 1)	5 (5)	1 (1)	0
Headache	28 (14)	0	NA	5 (5)	1 (1)	NA	12 (6)	0	3 (1)	0	0	NA
Constipation	27 (14)	1 (1)	0	19 (20)	1 (1)	0	3 (2)	1 (1)	0	3 (3)	0	0
Insomnia	21 (11)	0	NA	6 (6)	1 (1)	NA	1 (1)	0	NA	0	0	NA
Pyrexia	20 (10)	0	0	3 (3)	0	0	4 (2)	0	2 (1)	1 (1)	0	0
Vomiting	20 (10)	0	0	7 (7)	0	0	5 (3)	0	NA	1 (1)	0	0
Bleeding or hemorrhage events	48 (24)	9 (5)	1 (1)	12 (13)	2 (2)	1 (1)	21 (11)	1 (< 1)	0	5 (5)	0	1 (1)
Epistaxis	27 (14)	1 (1)	0	3 (3)	0	0	14 (7)	0	0	2 (2)	0	0
GI hemorrhage events	12 (6)	7 (4)	0	5 (5)	2 (2)	0	1 (1)	1 (1)	0	0	0	0
Hepatic hemorrhage events	1 (1)	0	1 (1)	0	0	0	0	0	0	0	0	0
Pulmonary hemorrhage events	5 (2)	1 (1)	0	0	0	0	0	0	0	0	0	0
Hypertension	49 (25)	25 (13)	0	12 (13)	5 (5)	0	32 (16)	15 (8)	0	6 (6)	2 (2)	0
Proteinuria	40 (20)	4 (2)	0	4 (4)	0	0	27 (14)	4 (2)	0	3 (3)	0	0
Arterial TE events	5 (3)	0	1 (1)	1 (1)	0	0	4 (2)	0	1 (1)	0	0	0
Venous TE events	2 (1)	0	0	2 (2)	1 (1)	0	1 (1)	0	0	1 (1)	0	0
GI perforation	2 (1)	2 (1)	0	2 (2)	2 (2)	0	1 (1)	1 (1)	0	0	0	0
Congestive heart failure	1 (1)	0	0	1 (1)	1 (1)	0	0	0	0	0	0	0
Fistula	1 (1)	0	0	0	0	0	0	0	0	0	0	0
Liver injury or failure	78 (40)	28 (14)	4 (2)	28 (29)	14 (15)	1 (1)	17 (9)	3 (2)	0	2 (2)	0	0
Ascites	35 (18)	7 (4)	0	7 (7)	2 (2)	0	4 (2)	1 (1)	0	1 (1)	0	0
Hepatic encephalopathy	8 (4)	5 (3)	1 (1)	0	0	0	2 (1)	1 (1)	0	0	0	0
Infusion related reactions	17 (9)	28 (14)	0	3 (3)	0	0	13 (7)	0	0	2 (2)	0	0

Adapted from: Zhu et al[57]. G: Grade; AE: Adverse event; NA: Not applicable; GI: Gastrointestinal; TE: Thromboembolic.

Citation: Personeni N, Pressiani T, Bozzarelli S, Rimassa L. Targeted agents for second-line treatment of advanced hepatocellular carcinoma. World J Gastrointest Oncol 2019; 11(10): 788-803
URL: https://www.wjgnet.com/1948-5204/full/v11/i10/788.htm
DOI: https://dx.doi.org/10.4251/wjgo.v11.i10.788